However, our clinical data revealed no statistically significant differences in RLN2 serum levels between CRC patients and controls, and it only demonstrated a weak connection with tumor stage, indicating that its diagnostic value is currently limited. This evidence concerns the gene RLN2 and colorectal carcinoma.